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Abstract
Estradiol plays a critical role in stimulating the fetal hypothalamus–pituitary–
adrenal axis at the end of gestation. Estradiol action is mediated through
nuclear and membrane receptors that can be modulated by ICI 182,780, a
pure antiestrogen compound. The objective of this study was to evaluate the
transcriptomic profile of estradiol and ICI 182,780, testing the hypothesis that
ICI 182,780 antagonizes the action of estradiol in the fetal hypothalamus.
Chronically catheterized ovine fetuses were infused for 48 h with: vehicle
(Control, n = 6), 17b-estradiol 500 lg/kg/day (Estradiol, n = 4), ICI 182,780
5 lg/kg/day (ICI 5 lg, n = 4) and ICI 182,780 5 mg/kg/day (ICI 5 mg,
n = 5). Fetal hypothalami were collected afterward, and gene expression was
measured through microarray. Statistical analysis of transcriptomic data was
performed with Bioconductor-R and Cytoscape software. Unexpectedly, 35%
and 15.5% of the upregulated differentially expressed genes (DEG) by Estra-
diol significantly overlapped (P < 0.05) with upregulated DEG by ICI 5 mg
and ICI 5 lg, respectively. For the downregulated DEG, these percentages
were 29.9% and 15.5%, respectively. There was almost no overlap for DEG
following opposite directions between Estradiol and ICI ICI 5 mg or ICI 5 lg.
Furthermore, most of the genes in the estrogen signaling pathway – after acti-
vation of the epidermal growth factor receptor – followed the same direction
in Estradiol, ICI 5 lg or ICI 5 mg compared to Control. In conclusion, estra-
diol and ICI 182,780 have estrogenic genomic effects in the developing brain,
suggesting the possibility that the major action of estradiol on the fetal
hypothalamus involves another receptor system rather than estrogen receptors.
Introduction
Preparation of the fetus for birth involves the interac-
tion of several endocrine systems. Estrogens, secreted by
the placenta, influence fetal hypothalamic function and
in turn, affect the timing of birth and fetal readiness
for life outside the uterus. In ruminants, for example,
initiation of parturition is a consequence of the neu-
roendocrine cascade between the components of the
hypothalamus-pituitary-adrenal (HPA) axis (Liggins
et al. 1973). Treatment of the fetus with physiologi-
cally relevant levels of estradiol or estradiol sulfate
increases circulating fetal ACTH and cortisol concentra-
tions (Saoud and Wood 1997; Winikor et al. 2011;
Wood 2011). We have assumed that the increase in
fetal HPA axis activity was mediated by estradiol bind-
ing to the estrogen receptor or, in the case of estradiol
sulfate, deconjugation of estradiol sulfate preceding the
binding of estradiol with the estrogen receptor (Wood
2011).
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ICI 182,780 is a selective estrogen antagonist that has
been shown to interfere with the nucleocytoplasmic shut-
tling of the estrogen receptor (ER) by blocking the
nuclear uptake of the receptor (Dauvois et al. 1993). This
drug has been a useful tool in basic science experiments
for assessing estrogen receptor-mediated actions of estro-
gens (Wakeling and Bowler 1992; Howell et al. 2000).
Clinically, it is used in the treatment of breast cancer
(among other applications), since it is an efficacious
antagonist of the proliferative actions of estrogen -ER
dependent- in reproductive organs such as the breast and
uterus (Howell et al. 2000). In previous experiments, we
used ICI 182,780 in in vivo experiments designed to test
the effect of estrogen receptor blockade on mRNA expres-
sion of CRH, propiomelanocortin (POMC) (Wood et al.
2001; Schaub et al. 2008b), ER (Schaub and Wood 2009)
and prostaglandin synthase-2 (PGHS2) (Schaub et al.
2008b), which are genes involved in the control of ACTH
secretion (Schaub et al. 2008b). These studies were based
in the assumption that estradiol action was primarily via
classical ER alpha (ESR1) and beta (ESR2) and that ICI
182,780 worked in vivo purely as an ER antagonist. How-
ever, the overall effect of blocking estrogen receptors in
the transcriptomic of fetal hypothalamus close to parturi-
tion – when the HPA axis activity is increasing – is still
unknown.
The objective of this study was to evaluate the fetal
hypothalamic transcriptomic response to intravenous
infusions of estradiol and ICI 182,780 at different doses
during 2 days in late gestation, testing the hypothesis that
ICI 182,780 has an action opposite to that of estradiol in
the fetal hypothalamus. We used an Agilent microarray of
ovine transcripts that we annotated, assigned human gene
names, and have used for other studies to investigate the
mechanism of responses to various stimuli, including fetal
hypoxia (Wood et al. 2013, 2016; Chang et al. 2016) and
cerebral hypoperfusion (Wood et al. 2014). Array annota-
tion has been validated in these and other studies.
Materials and Methods
Animal procedures
All these experiments were performed in accordance with
the Guiding Principles for Research Involving Animals
and Human Beings published by the American Physiolog-
ical Society and were approved by the University of Flor-
ida Institutional Animal Care and Use Committee. A
total of 11 pregnant ewes were used in this study. Three
ewes were carrying singletons, and the other 8 were preg-
nant with twin fetuses. The gestational age at the time of
surgery was 124–126 days of gestation (term: ~145 days
of gestation). The fetuses were randomly assigned to the
groups at the time of surgery. If the fetuses were twins,
both animals were assigned to the same treatment group.
Three sets of twin fetuses (n = 6 total) were infused with
DMSO:water::50:50 vehicle solution (n = 4) or were
catheterized but did not receive infusions (n = 2; Control
group), two sets of twins were administered 17b-estradiol
500 lg/kg/day infusion (Estradiol, n = 4); another two
sets were administered ICI 182,780 5 lg/kg/day infusion
(ICI 5 lg, n = 4) and three singletons and one set of twin
were treated with ICI 182,780 5 mg/kg/day infusion (ICI
5 mg, n = 5). For all experiments, estradiol was pur-
chased from Sigma Chemical (catalog number E8875, St.
Louis, MO), ICI 182,780 was purchased from Tocris Bio-
sciences (catalog number 1047, Bristol, UK), and DMSO
was purchased from Sigma Chemical. The estradiol dose
(500 lg/kg/day infusion) is known to produce physiologi-
cal increases in fetal plasma estradiol concentration, and
the dose of ICI 182,780 was scaled to the estradiol dose
(5 lg/kg/day infusion). However, to avoid bias on the
action of ICI 182,780 due to the increasing number of
estrogen receptors in the developing brain, we arbitrarily
increased the dose 1000 times to 5 mg/kg/day infusion.
All animals were housed in individual pens located in the
Animal Resources Department at the University of
Florida. The rooms maintained controlled lighting and
temperature, and sheep were given food and water ad
libitum.
Food was withheld from the pregnant ewes for 24 h
before surgery. Ewes were intubated and anesthetized with
halothane (0.5–2%) in oxygen before and during surgical
preparation as previously described (Wood et al. 2003).
Surgery and catheter placement for all fetuses were per-
formed using an aseptic technique as previously
described, with femoral arterial, and venous catheters as
well as amniotic fluid catheters (Wood et al. 2003; Schaub
et al. 2008b). Vascular catheters were exteriorized through
the flank of the ewe using a trochar, where they were
maintained in a removable synthetic cloth pocket. Ewes
were treated with 1 mg/kg flunixin meglumine (Webster
Veterinary, Sterling, MA) for analgesia and returned to
their pens where they were monitored until they could
stand on their own. If needed, a second treatment with
flunixin meglumine was administered 24–48 h after the
first treatment with this drug. Twice daily during a 5-day
recovery period, ewes were treated with an antibiotic
(ampicillin, 750 mg im: Polyflex, Fort Dodge Laborato-
ries, Fort Dodge, IA) or Cefazolin (11–22 mg/kg, iv or
im) and rectal temperatures were monitored for indica-
tion of postoperative infection. None of the animals
included in this study showed any signs of postoperative
infection.
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Experimental procedure and blood sample
collection
After the 5-day recovery period, compounds (estradiol,
ICI 5 lg/kg, ICI 5 mg/kg and vehicle) were infused into
the fetuses intravenously. Infusions were continued for
48 h, allowing enough time for genomic actions after
alteration of steroid action. The infusions were delivered
with an SAI MiniBT Infusion pump (Strategic Applica-
tions Inc., Chicago, IL), which was calibrated to dispense
the 10 mL continuously and uniformly during the 48 h
treatment period.
Tissue sample collection
Pregnant ewes and fetuses were euthanized with an over-
dose of sodium pentobarbital after the 48 h of the treat-
ment period. Brains were rapidly removed, dissected into
distinct regions, and snap frozen in liquid nitrogen. Tis-
sues were collected from brain regions and selected organs
and archived for other experiments. In the present
microarray experiment, we analyzed gene expression in
the hypothalamus because of its critical role in endocrine
control mechanisms, including fetal stress responses and
timing of birth in the sheep (McDonald and Nathanielsz
1991). Dissection of the hypothalamus from the fetal
brain was performed as described in Gersting et al.
(2009) and in Schaub et al. (2008a). Hypothalamus was
removed as a single block of tissue, boundedon the rostral
edge by the rostral edge of the optic chiasm, on the cau-
dal side by the caudal edge of the median eminence, and
on the sides by the edges of the median eminence.
RNA extraction and preparation
RNA was extracted from the entire hypothalamus using
Trizol (Invitrogen, Carlsbad, CA) following the manufac-
turer’s directions. The RNA was resuspended in RNAse-
cure, and stored at 80°C in aliquots until use. For
microarray analysis, 60 lg of these RNAs were DNase
treated using the Turbo RNase-free DNase kit (Ambion,
Foster City, CA), the concentration determined with a
Nanodrop spectrophotometer (ND-1000, ThermoFisher,
Wilmington, DE) and the integrity of the RNA was mea-
sured using an Agilent Bioanalyzer, 2100 model. The
RNA Integrity Number (RIN) value for the RNAs ranged
from 7.1 to 8.6. One microgram of the DNase-treated
RNA was labeled with Cyanine 3 (Cy3) CTP with the
Agilent Quick Amp kit (5190-0442, New Castle, DE)
according to their methodology, purified with the Qiagen
RNeasy kit (Valencia, CA) according to Agilent’s revision
of the Qiagen protocol as shown in the Quick Amp kit
protocol except that the microcentrifugation spins were
performed at room temperature instead of 4°C. The
resulting labeled cRNA was analyzed with the NanoDrop
spectrophotometer, and the specific activities and the
yields of the cRNAs were calculated; these ranged from
10.22 to 12.38 pmol Cy3/lg RNA and from 5.6 to 8.9 lg,
respectively. The labeled cRNA was stored at 80°C until
use.
Microarray hybridization
This was performed following protocols from Agilent.
Briefly, 600 ng of each labeled cRNA was fragmented and
then mixed with hybridization buffer using the Agilent
gene expression hybridization kit. These were applied to
an ovine 8 X 15 K array slide (Agilent 019921), contain-
ing 8 arrays with 15,208 oligomers with a length of 60
bases and hybridized at 65°C for 17 h at 10 rpm. The
arrays were washed, dried, stabilized, and scanned with an
Agilent G2505B 2 dye scanner at the Interdisciplinary
Center for Biotechnology Research at the University of
Florida. Features were extracted with Agilent Feature
extraction 9.1 software. Microarray data have been depos-
ited in the NCBI Gene Expression Omnibus under acces-
sion number GSE99497.
Statistical analysis
The limma package was used to import the raw data into
R (http://www.r-project.org), perform background correc-
tion and normalize the data using the quantile normaliza-
tion method (Smyth 2005). Control probes and low
expressed probes were filtered out, retaining for further
analysis the probes that were at least 10% brighter than
the negative controls on at least four arrays. Batch effects
between slides were removed with the ComBat function
of the SVA package (Johnson et al. 2007). Then, the
limma package was used for the statistical analysis, apply-
ing the empirical Bayes method proposed by Smyth
(Smyth 2004). This method calculates a moderated t-sta-
tistic for differential expression for each gene by perform-
ing a linear model fit on the data. An empirical Bayes
step is applied to moderate the standard errors of the
estimated log-fold changes and produce more stable esti-
mates, especially when the number of replicates is small.
Each treatment group was compared with the control
group. A gene was considered to be significantly differen-
tially expressed (over or under expressed) if both of the
following conditions were met: (1) the ratio of the nor-
malized intensity in the treatment fetus sample to nor-
malized intensity in the control fetus sample was higher
or lower than a twofold change (up or downregulation,
respectively); and (2) differences were considered statisti-
cally significant at P ≤ 0.05.
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Data comparison
Up and downregulated differentially expressed genes
(DEG) by each of the treatments were compared to each
other to determine the overlap of DEG between them.
Statistical comparisons were made by the test indepen-
dence (Pearson’s chi-square test) to determine the relat-
edness between up or downregulated DEG by estradiol
and up or downregulated DEG by ICI 5 lg or ICI 5 mg.
Clustering analysis
The network inference and clustering analysis were per-
formed using Cytoscape version 3.6.0 (Smoot et al. 2011),
through the following plugins: GeneMania, ClusterONE,
and BINGO. GeneMania was used to infer networks of
functionally related genes (Warde-Farley et al. 2010)
using known functional associations from the Homo sapi-
ens database. The list of human official symbols for the
genes of interest was input into the GeneMania plugin to
retrieve the corresponding association network. The net-
work was inferred for the upregulated and downregulated
genes for each of the treatments compared to the control.
These networks were merged using the Merge plugin,
included in the Cytoscape core, in order to detect over-
lapped genes between networks. Four types of merges
were performed (1) between the networks composed of
upregulated genes for each treatment; (2) between net-
works composed of downregulated genes for each treat-
ment, (3) between networks inferred with upregulated
genes for the estradiol treatment and downregulated genes
for ICI (both doses) treatments and (4) between networks
containing downregulated genes for the estradiol treat-
ment and upregulated genes for ICI (both doses) treat-
ments.
ClusterONE was used to discover densely connected
and possibly overlapping regions (clusters) within subnet-
works (Nepusz et al. 2012). A P-value is calculated for
each cluster, based on the one-sided Mann–Whitney U
test performed on the in-weights and out-weights of the
vertices. An in-weights value significantly larger than the
out-weights value would indicate a valid cluster and not
the result of random fluctuations. Thus, a P-value is
assigned to the cluster. Only the clusters with a P-value
less than 0.05 were considered in further analyses.
BiNGO was run to determine which biological pro-
cesses are statistically overrepresented in the set of genes
corresponding to the identified cluster (Maere et al.
2005). The statistical test employed was the hypergeomet-
ric test (equivalent to the Fisher test). The threshold P-
value was 0.05, after correction by the Bonferroni
method.
Differential expression testing for genes in
a KEGG pathway network
Despite the overrepresented biological processes identified
with BiNGO (see above), it was expected that genes in
the estrogen signaling pathway would follow opposite
directions in Estradiol and ICI 5 lg or ICI 5 mg com-
pared with the control group. To prove this hypothesis,
the KEGG pathway “map04915” (estrogen signaling path-
way) was first translated into a gene network with the
KEGGraph package (Zhang and Wiemann 2009). Then,
the DEGraph package (Jacob et al. 2012) was used to test
whether this gene network was differentially expressed
between Estradiol, ICI 5 lg or ICI 5 mg and the control
group. As result, significant subnetworks composed by
nodes that are colored according to the t-statistics (or t-
score) for the mean difference of expression between the
two conditions for each gene were obtained. This method
takes into account the topology of the network to yield
more powerful detection procedures than the classical
two-step approaches, which first test individual genes,
then test gene sets for enrichment in DEG.
Results
In the fetal hypothalamus, intravenous infusion of estra-
diol upregulated 349 genes and downregulated 251 genes.
In comparison, ICI 182,780 treatment upregulated 457
and downregulated 378 genes when administered in a
dose of 5 lg/kg, and upregulated 401 and downregulated
358 genes when administered in a dose of 5 mg/kg. Sur-
prisingly, there was significant overlap between differen-
tially expressed genes (DEG) altered in the same direction
(up or downregulated DEG, Fig. 1A and B, respectively)
but no significant overlap for genes altered in the oppo-
site direction (Fig. 1C and D) by Estradiol and ICI (5 lg
or ICI 5 mg). These results suggested a similar transcrip-
tomic response in the fetal hypothalamus after ICI 182,
780 or estradiol infusions for 48 h.
To confirm this finding, up and downregulated DEG
were organized into inferred networks and visualized with
the Cytoscape software. The nodes (i.e., DEG) of the net-
works were related to each other if they accomplished at
least one of the following criteria: to belong to the same
pathway, to be coexpressed, to present physical (protein–
protein) or genetic interactions, to be colocalized, to share
protein domains, or to be predicted to interact in other
organisms. The number of nodes in the networks inferred
with the upregulated DEG was 344 for the estradiol treat-
ment, 388 for the ICI 5 mg treatment and 438 for the ICI
5 lg treatment. For the downregulated DEG, the number
of nodes in each network was 242 for the estradiol
2018 | Vol. 6 | Iss. 18 | e13871
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treatment, 343 for the ICI 5 mg treatment, and 367 for
the ICI 5 lg treatment.
These networks were merged to visualize the overlap-
ping nodes between them (Fig. 2). In concordance with
the Venn Diagrams shown in Figure 1, there was a strong
overlap between networks of upregulated DEG for each of
the three treatments (Fig. 2A) as well as between net-
works of downregulated DEG for each of the three treat-
ments (Fig. 2B). The overlap was even more evident
between the networks of DEG in the estradiol group and
ICI 5 mg group. However, there was little overlap
between networks of DEG following opposite directions
in the estradiol group as compared to either the ICI 5 mg
group or ICI 5 lg group (Fig. 2C and D). Thus, the tran-
scriptomic effects for the treatment with both doses of
ICI 182, 780 in the fetal hypothalamus are rather similar
to the transcriptomic effects of estradiol, at least after
48 h of infusion. Next, in order to determine the func-
tional significance of these findings, we interrogated the
merged networks displayed in Figures 2A and B for clus-
ters of genes in the overlapping and nonoverlapping
regions of the merged network. Statistically overrepre-
sented biological processes for these clusters are summa-
rized in Table 1A and B, respectively (redundant
biological processes were simplified).
Despite the overrepresented biological processes sum-
marized in Table 1, we explored the question of whether
genes part of the known estrogen signaling pathway
would follow opposite directions in Estradiol and ICI
5 lg or ICI 5 mg compared to the control group. Using
a pathway-driven approach, we tested the KEGG pathway

















ICI 5 µg 
B
ICI 5 mg ICI 5 mg 
249 
337 391 64* 
2 
Estradiol 
ICI 5 µg 
C








ICI 5 µg 
D
ICI 5 mg 
Figure 1. Venn diagrams showing the overlap for the differentially expressed genes (DEG) in fetal hypothalami after 48 h treatment with
17b-estradiol (500 lg/kg/day; Estradiol, n = 4), low dose of ICI 182,780 (5 lg/kg/day; ICI 5 lg, n = 4) or high dose of ICI 182,780
(5 mg/kg/day; ICI 5 mg, n = 5), compared to controls (n = 6). (A) Upregulated DEG by all the treatments. (B) Downregulated DEG by all the
treatments. (C) Downregulated DEG by Estradiol and upregulated DEG by both doses of ICI 182,780. (D) Upregulated DEG by Estradiol and
downregulated DEG by both doses of ICI 182,780. (*P < 0.05 by Pearson chi-square test).
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network, in Estradiol, ICI 5 mg or ICI 5 lg, versus the
control group. The resulting significant subnetworks
(Fig. 3) showed the same signaling pathway for all groups
compared with the controls: activation of the epidermal
growth factor receptor (EGFR), which is a member of a
membrane-initiated steroid-signaling pathway (Filardo
2002). Most of the downstream nodes on the pathway
changed the same direction in Estradiol, ICI 5 mg or ICI
5 lg compared to the control group. The subnetworks
for Estradiol and ICI 5 mg (Fig. 3A and B, respectively)
contained these similarly upregulated nodes: EGFR,
AKT1, AKT2, SHC1, SOS2, ESR1, and ATF4; and the fol-
lowing downregulated nodes: PIK3R1, PIK3R2, PIK3CB,
GRB2, NRAS, RAF1, MAP2K1, MAP2K2, MAPK1,
MAPK3, PRKACA, CREB1, and ATF2. Only PRKACB,
SOS1, ESR2, and CREB3 were changed in opposite direc-
tions. The subnetworks for Estradiol and ICI 5 lg
(Fig. 3A and 3C, respectively) contained the following
upregulated nodes in common: EGFR, SHC1, SOS1,
SOS2, ESR1, and ATF4; and the following downregulated
nodes: PIK3R2, PIK3CB, NRAS, RAF1, MAP2K1,
MAP2K2, MAPK1, MAPK3, and PRKACA. The nodes
with opposite directions were GRB2, AKT1, AKT2,
PIK3R1, PRKACB, ESR2, CREB1, and CREB3.
As mentioned above, most of the nodes in the signaling
pathway followed the same direction in Estradiol, ICI
5 lg or ICI 5 mg groups compared with the control
group. The direction of the genes corresponding to fac-
tors found within the cytoplasm could vary relative to the
dynamics of the responses to the different ligands since it
has been shown that recruitment of the downstream sig-
naling proteins differs between EGFR agonists and also
between different doses of the same agonist (Ronan et al.
2016). However, it is interesting to note that the mem-
brane receptor (EGFR) and one of the most important
nuclear ligand-activated transcription factors for estradiol
Estradiol 
ICI 5 mg 
ICI 5 µg 
A 
Estradiol 
ICI 5 mg 
ICI 5 µg 
B 
ICI 5 µg 
Estradiol 
ICI 5 mg 
C 
ICI 5 µg 
ICI 5 mg 
Estradiol 
D 
Figure 2. Merged networks of functionally related differentially expressed genes (DEG) in fetal hypothalami after 48 h treatment with
17b-estradiol (500 lg/kg/day; Estradiol, n = 4), low dose of ICI 182,780 (5 lg/kg/day; ICI 5 lg, n = 4) or high dose of ICI 182,780
(5 mg/kg/day; ICI 5 mg, n = 5), compared to controls (n = 6). (A) Upregulated DEG by all the treatments. (B) Downregulated DEG by all the
treatments. (C) Downregulated DEG by Estradiol and upregulated DEG by both doses of ICI 182,780. (D) Upregulated DEG by Estradiol and
downregulated DEG by both doses of ICI 182,780. Blue nodes denote the overlapped DEG between the networks.
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(ESR1) are upregulated in all the treatments, although the
difference of expression for these genes between the trea-
ted and control fetuses in the general statistical analysis
was not significant.
These findings reinforce the concept that, after 48 h of
infusion, ICI 182,780 exerts an estrogenic effect in the
ovine fetal hypothalamus.
Discussion
This study demonstrates that the transcriptomic response
to a 2 days infusion of ICI 182,780 is similar to, not
opposite to, the transcriptomic response to a 2 days
infusion of estradiol (Figs. 1 and 2, panels A–B). The
concordance of differential gene expression patterns in
the Estradiol and ICI 182,780 treatment groups resulted
in an overlap of biological processes (Tables 1). Also,
Estradiol and ICI 182,780 treatments stimulate the estro-
gen-signaling pathway in a similar fashion (Fig. 3). ESR1
was shown to be upregulated by all the treatments,
although the difference was not statistically significant.
In the rat brain, estrogen exposure downregulated ESR1
(Brown et al. 1996). In the ovine fetal hypothalamus,
estradiol treatment did not modify the mRNA expres-
sion of ESR1 but downregulated its protein levels
(Wood 2008). To determine the physiological changes in
ESR1 and ESR2 mRNA ontogenies, we re-analyzed the
microarray results from ovine fetal hypothalamic samples
obtained at 80, 100, 120, 130, 145 days of gestation and
1 day of extrauterine life (Rabaglino et al. 2014). We
found that ESR1 mRNA expression followed an increas-

















































































Figure 3. Subnetworks obtained after testing the “estrogen signaling pathway” network (KEGG pathway: map04915) in differentially
expressed genes in fetal hypothalami after 48 h of treatment with (A) 500 lg/kg/day of 17b-estradiol (n = 4); (B) 5 mg/kg/day of ICI 182,780
(n = 5); and (C) 5 lg/kg/day of ICI 182,780 (n = 4); compared to controls (n = 6). T-score refers to the t-statistics obtained after applying
individual t-test to each gene comparing both conditions (treatments vs. control).
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gestation compared to the other gestational ages but
decreased at 1 day of life. ESR2 mRNA expression
remained mostly unchanged (Fig. S1). In order to cor-
roborate these microarray results, mRNA levels were also
determined by qRT-PCR. ESR1 mRNA expression fol-
lowed the increasing trend, although the higher levels
were observed at 1 day of life, to decrease at 1 week of
life. ESR2 expression remained unchanged (Fig. S2, A–
B). Circulating estrogen levels in the ovine fetus increase
toward the end of gestation, playing a critical role in
brain maturation and stimulation of the HPA axis for
parturition (Wood 1999, 2005, 2014). Thus, the action
of exogenous estradiol treatment on ESR1 expression
may depend on the time of gestation and level of matu-
ration of the fetal brain.
There is ample evidence that ICI 182,780 interacts
directly with the estrogen receptor. ICI 182,780 is a
structural analog of 17b estradiol and binds ESR1 and
ESR2 with similar affinity compared to that of 17b
estradiol. The mechanism of action of ICI 182,780 is
associated with a conformational change at the estro-
gen receptor, which in turn seemingly impairs the
dimerization (Brzozowski et al. 1997) and nuclear
uptake of the receptor, both necessary steps for bind-
ing the receptor to its DNA binding site (Dauvois
et al. 1993). In addition, other mechanisms specific to
mammalian cells can also trigger an antiestrogen activ-
ity of ICI 182,780, including compound-receptor bind-
ing caused by different cytoplasmic components or
disruption of the cytoplasm-to-nuclear transport sys-
tems (Dudley et al. 2000).
However, ICI 182,780 has been shown to have ago-
nist activity in some systems. In yeast, which lack
endogenous nuclear receptors and co-regulatory pro-
teins of other receptors, (Walfish et al. 1997), ICI
182,780 induced dimerization and transcriptional activ-
ity of transfected ER and so it did not antagonize the
effect of estradiol (Dudley et al. 2000). In fish, ICI
182, 780 induced an agonist response to estradiol at
the level of gene expression in liver but not in testis
(Pinto et al. 2006). Thus, ICI 182,780 is known to be
a selective ER modulator, but its mechanism of action
can differ among the species, cell type, and probably
other variables as well. Indeed, for mammalian cells,
the effect of ICI 182,780 has been shown not to be
exclusively estrogen antagonist, at least in tissues other
than adult reproductive tissues such as breast and
uterus. Interestingly, agonist effects of ICI 182,780 have
been observed in the brain in several studies in vitro.
In one study, ICI 182,780 activated neuronal responses
similar to 17b estradiol to induce neuronal plasticity
and neuroprotection in fetal rat hippocampal neurons
(Zhao et al. 2006). Also, 17b estradiol and ICI 182,780
were shown to activate ERK1/2 MAPK signaling in
developing and mature cerebellar neurons, and the
continuous exposure to estradiol had an antimitotic
effect (Wong et al. 2003). Another study demonstrated
that 17b estradiol stimulated axon growth in hypotha-
lamic neurons in vitro, and this effect was not blocked
with ICI 182,780 (Cambiasso and Carrer 2001). There-
fore, these in vitro studies demonstrated a similar
effect for both 17b estradiol and ICI 182,780 in the
developing brain.
In this study, the upregulated DEG by all treatments
were significantly enriched for biological processes such as
angiogenesis and cell migration, which are critical during
fetal development (Table 1A). Estrogen has shown to
induce angiogenesis in brain tissues (Krause et al. 2006)
or to stimulate actin cytoskeleton remodeling, cell adhe-
sion and cell migration (Giretti and Simoncini 2008).
Our results are consistent with these actions, and they
suggest that ICI 182,780 is rather an agonist than an
antagonist of estradiol regarding these actions. The over-
represented biological processes enriched with the down-
regulated DEG by all the treatments were mostly related
to the mitochondrial respiratory chain (Table 1B). Estra-
diol has complex actions on the respiratory chain. Several
works have demonstrated that 17b estradiol enhances
mitochondrial efficiency and induces the transcription of
mitochondrial respiratory chain protein, as reviewed by
Chen et al. (2009). However, 17b estradiol decreased
mitochondrial respiratory activity and oxidative phospho-
rylation in liver cells, and these effects were not sup-
pressed with ICI 182,780 (Moreira et al. 2006). In
addition, 17b estradiol inhibited mitochondrial electron
transport in homogenates of rat uterus, liver, and skeletal
muscle (Kuss and Jutting 1967). Therefore, the action of
17b estradiol on the respiratory chain depends upon the
context, tissue type (Moreira et al. 2011), and age
(Alvarez-Delgado et al. 2010). Downregulation of genes
related to the cell cycle occurs physiologically in the ovine
fetal brain during the last stage of gestation (Rabaglino
et al. 2014). It is possible that physiologically, circulating
estradiol decreases the mitochondrial respiratory function
as part of the adaptive mechanism that balances the
increased oxygen demand with the limited supply of oxy-
gen through the umbilical artery.
Results from this study are not showing that the estro-
gen receptor in the ovine fetal hypothalamus behaves bio-
chemically in a manner different from the estrogen
receptor of other species or at another time during the
life. Rather, the present results suggest that both ICI
182,780 and estradiol activate a separate pathway that is
not mediated by either ESR1 or ESR2. Results obtained
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after testing the differential expression of genes in the
estrogen signaling pathway network (Fig. 3) suggest that
in the fetal brain, binding of ICI 182,780 or estradiol to
the membrane EGFR activates similar downstream signal-
ing cascade. Also, it is possible that both estradiol and
ICI 182,780 bind to GPR30 (GPER), a transmembrane G-
protein-coupled receptor that has been shown to transac-
tivate EGFR (Filardo 2002; Ge et al. 2012). ICI 182,780 is
known to bind this receptor with high affinity (Thomas
et al. 2005), and the transcriptomic responses to both ICI
182,780 and estradiol are consistent with activation of
downstream pathways activated by GPR30. The mRNA
expressions of GPR30 in the ovine fetal hypothalamus
from 80 days of gestation to 1 week of extra-uterine life
were measured through qRT-PCR (Fig. S2C). We found
that the expression of GPR30 is significantly increasing at
130 days of gestation, to decrease before birth. However,
mRNA levels increase again at 1 day of life but strongly
decrease at 1 week.
The action of estradiol and ICI 182,780 on ESR1 or
GPR30 may depend upon the abundance of these recep-
tors in the developing brain, since estradiol has higher
affinity for GPR30 (Kd: 2.7 nmol/L (Thomas et al. 2005))
than for ESR1 (Kd: 5.9 nmol/L (Weichman and Notides
1980)). Interestingly, mRNA levels of GPR30 in the ovine
hypothalamus are significantly higher than mRNA levels
of ESR1 at all ages from 80 days of fetal life to 1 week of
extra-uterine life, as measured through qRT-PCR
(Fig. S3). This difference ranged from 2.3 folds at 1 week
of life to seven folds higher at 120–130 days of fetal life,
coincident with the gestational ages when surgeries were
performed. Thus, we can speculate that the main actions
of estradiol and ICI 182,780 on the hypothalamic tran-
scriptomics would be through the binding to GPR30 and
transactivation of EGFR, inducing a parallel downstream
signaling and consequently, a similar transcriptmic
response (Fig. 4). Further studies could elucidate the roles
of GPR30 in the developing fetal brain.
Conclusion
We conclude that the transcriptomic response to ICI
182,780 in the fetal hypothalamus is similar to that of
estradiol, and that ICI 182,780 does not block the actions
of estradiol in this fetal brain region. Our findings suggest
the possibility that the major action of estradiol on the
fetal hypothalamus may not involve the estrogen receptor,
but rather involve other receptor systems, such as GPR30.
This is an intriguing idea that could inform a better
understanding of estrogenization of the developing brain
or of estrogen modulation in the endocrinology of the
late gestation fetus.
Estradiol ICI 182,780 







Figure 4. Diagram of Estradiol action on the fetal brain. Estradiol binds estrogen receptor alpha (ESR1), inducing its dimerization and nuclear
translocation, which can be blocked by ICI 182,780. However, Estradiol and ICI 182,780 bind with high affinity, a transmembrane G-protein-
coupled receptor (GPR30) which in turn could transactivate epidermal growth factor receptor (EGFR). Green arrow: stimulation, red arrow:
inhibition.
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Figure S1. Ontogeny of mRNA expression for (A) estro-
gen receptor alpha (ESR1) and (B) estrogen receptor
alpha beta (ESR2) in the ovine fetal hypothalamus from
80 days of gestation to 1 day of extrauterine life (EUL).
Expression levels were measured through microarray tech-
nology using an Agilent platform. Data are fold differ-
ences relative to mean expression at 80 days. a: different
from 80 days values; b: different from 100 days values; c:
different from 120 days values; d: different from 130 days
values; e: different from 145 days values. For all statistical
comparisons, P < 0.05 was used as the criterion for sig-
nificance.
Figure S2. Ontogeny of mRNA expression for (A) estro-
gen receptor alpha (ESR1); (B) estrogen receptor beta
(ESR2) and (C) G-protein-coupled estrogen receptor 1
(GPR30) in the ovine fetal hypothalamus from 80 days
(d) of gestation to 1 week of extrauterine life (EUL).
Expression levels were measured by qRT-PCR. Data are
fold differences relative to mean expression at 80 days. a:
different from 80 days values; b: different from 100 day
values; c: different from 120 day values; d: different from
130 days values; e: different from 145 days values. For all
statistical comparisons, P < 0.05 was used as the criterion
for significance.
Figure S3. mRNA expression of to G-protein-coupled
estrogen receptor 1 (GPR30) and estrogen receptor beta
(ESR2) relative to estrogen receptor alpha (ESR1) in the
ovine fetal hypothalamus from 80 days of gestation to
1 week of extrauterine life (EUL). Expression levels were
measured by qRT-PCR. Grey Bars: ESR1, black bars:
GPR30, white bars: ESR2. (*) different from ESR1 values.
For all statistical comparisons, P < 0.05 was used as the
criterion for significance.
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